Next Article in Journal
Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature
Previous Article in Journal
Integrating Patient-Centred Research in the Canadian Cancer Trials Group
Review

Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects

1
School of Medicine, Georgetown University, Washington, DC 20007, USA
2
School of Medicine, Louisiana State University Shreveport, Shreveport, LA 71103, USA
3
Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95211, USA
4
Department of Anesthesiology, Louisiana State University Shreveport, Shreveport, LA 71103, USA
5
Paolo Procacci Foundation, Via Tacito 7, 00193 Roma, Italy
6
College of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85724, USA
7
Department of Anesthesiology, School of Medicine, Creighton University, Omaha, NE 68124, USA
8
Valley Anesthesiology and Pain Consultants—Envision Physician Services, Phoenix, AZ 85004, USA
9
Southcoast Health, Southcoast Physicians Group Pain Medicine, Wareham, MA 02571, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(1), 640-660; https://doi.org/10.3390/curroncol28010063
Received: 14 December 2020 / Revised: 9 January 2021 / Accepted: 18 January 2021 / Published: 21 January 2021
Multiple myeloma (MM) is a hematologic malignancy characterized by excessive clonal proliferation of plasma cells. The treatment of multiple myeloma presents a variety of unique challenges due to the complex molecular pathophysiology and incurable status of the disease at this time. Given that MM is the second most common blood cancer with a characteristic and unavoidable relapse/refractory state during the course of the disease, the development of new therapeutic modalities is crucial. Belantamab mafodotin (belamaf, GSK2857916) is a first-in-class therapeutic, indicated for patients who have previously attempted four other treatments, including an anti-CD38 monoclonal antibody, a proteosome inhibitor, and an immunomodulatory agent. In November 2017, the FDA designated belamaf as a breakthrough therapy for heavily pretreated patients with relapsed/refractory multiple myeloma. In August 2020, the FDA granted accelerated approval as a monotherapy for relapsed or treatment-refractory multiple myeloma. The drug was also approved in the EU for this indication in late August 2020. Of note, belamaf is associated with the following adverse events: decreased platelets, corneal disease, decreased or blurred vision, anemia, infusion-related reactions, pyrexia, and fetal risk, among others. Further studies are necessary to evaluate efficacy in comparison to other standard treatment modalities and as future drugs in this class are developed. View Full-Text
Keywords: belantamab mafodotin; multiple myeloma; anti-B cell maturation antigen; antibody drug conjugate; chronic pain belantamab mafodotin; multiple myeloma; anti-B cell maturation antigen; antibody drug conjugate; chronic pain
MDPI and ACS Style

Lassiter, G.; Bergeron, C.; Guedry, R.; Cucarola, J.; Kaye, A.M.; Cornett, E.M.; Kaye, A.D.; Varrassi, G.; Viswanath, O.; Urits, I. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Curr. Oncol. 2021, 28, 640-660. https://doi.org/10.3390/curroncol28010063

AMA Style

Lassiter G, Bergeron C, Guedry R, Cucarola J, Kaye AM, Cornett EM, Kaye AD, Varrassi G, Viswanath O, Urits I. Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Current Oncology. 2021; 28(1):640-660. https://doi.org/10.3390/curroncol28010063

Chicago/Turabian Style

Lassiter, Grace, Cole Bergeron, Ryan Guedry, Julia Cucarola, Adam M. Kaye, Elyse M. Cornett, Alan D. Kaye, Giustino Varrassi, Omar Viswanath, and Ivan Urits. 2021. "Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects" Current Oncology 28, no. 1: 640-660. https://doi.org/10.3390/curroncol28010063

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop